anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Research Assistants (RAs) will verbally administer baseline survey and insert Dexcom G6 CGM, before unveiling the group assignment. CGM data will be transmitted from bedside iPhone to web-based platforms for: (1) Real-Time Management (via iPad-based FOLLOW app used by bedside RN and Digital Dashboard used by remote monitoring team) and (2) Clinical Optimization (via CLARITY, a Diabetes RN Coordinator will conduct remote clinical management of patients from a central, Scripps Diabetes Hub). A post-CGM satisfaction survey will be administered and compensation provided when CGM is removed prior to discharge or within 2 weeks following discharge. The CGM readings will be used to make recommendations for insulin adjustment and glucose management. After discharge, CGM data will be downloaded from a HIPPA-compliant, web-based CGM data management tool, and saved in Excel. The Data Analyst, blinded to condition, will routinely screen CGM data and merge individual spreadsheets for analysis.
BACKGROUND: Powdery mildew (caused by Blumeria graminis f. sp. tritici (Bgt)) and leaf rust (caused by Puccinia triticina (Pt)) are prevalent diseases in wheat (Triticum aestivum L.) production. Thinopyrum ponticum (2n = 10x = 70, EeEeEbEbExExStStStSt) contains genes that confer high levels of resistance to these diseases.
RESULTS: An elite wheat-Th. ponticum disomic substitution line, DS5Ag(5D), was developed in the Bainong Aikang 58 (AK58) background. The line was assessed using genomic in situ hybridization (GISH), oligo-nucleotide probe multiplex (ONPM) fluorescence in situ hybridization (FISH), and molecular markers. Twenty eight chromosome-specific molecular markers were identified for the alien chromosome, and 22 of them were co-dominant. Additionally, SNP markers from the wheat 660 K SNP chip were utilized to confirm chromosome identification and they provide molecular tools for tagging the chromosome in concern. The substitution line demonstrated high levels of resistance to powdery mildew throughout its growth period and to leaf rust at the adult stage. Based on the resistance evaluation of five F5 populations between the substitution lines and wheat genotypes with different levels of sensitivity to the two diseases. Results showed that the resistance genes located on 5Ag confered stable resistance against both diseases across different backgrounds. Resistance spectrum analysis combined with diagnostic marker detection of known resistance genes of Th. ponticum revealed that 5Ag contained two novel genes, Pm5Ag and Lr5Ag, which conferred resistance to powdery mildew and leaf rust, respectively.
CONCLUSIONS: In this study, a novel wheat-Th. ponticum disomic substitution line DS5Ag(5D) was successfully developed. The Th. ponticum chromosome 5Ag contain new resistance genes for powdery mildew and leaf rust. Chromosomic-specific molecular markers were generated and they can be used to track the 5Ag chromosome fragments. Consequently, this study provides new elite germplasm resources and molecular markers to facilitate the breeding of wheat varieties that is resistant to powdery mildew and leaf rust.
Patients receive trastuzumab IV over 15 minutes immediately before receiving copper Cu 64-DOTA-trastuzumab IV on day 0. Patients undergo PET scans at 18-24 and 42-48 hours, on day 1 and day 2. Within 4 days after completion of PET scans, patients receive trastuzumab IV over 30-90 minutes weekly or every 3 weeks and pertuzumab IV over 30-60 minutes. Treatment repeats every 21 days for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo surgery after 6 cycles of trastuzumab and pertuzumab.
The invention comprises an aqueous solution containing polyoxymethylenes with or without a minor proportion of monomeric formaldehyde, the solution containing approximately 30% by weight of formaldehydic material (i.e. polymer plus monomer if any) and at least one mono- or poly-hydric aliphatic alcohol of low dielectric constant (i.e. not greater than 33.7) as a stabilizer, and a process for preparing such a solution in which an aqueous solution of formaldehyde containing methanol, ethanol or ethylene glycol is maintained at acid pH and approximately ambient temperature for 6-10 days, after which a further aqueous solution of polyoxymethylene is added to precipitate high polymeric material and to adjust the concentration of formaldehydic material to approximately 30% by weight, solid material is separated from the solution and then at least one mono- or polyhydric aliphatic alcohol of low dielectric constant is added.ALSO:Pharmaceutically valuable, stable aqueous solutions of polyoxymethylenes (with or without a minor proportion of monomeric formaldehyde) contain approximately 30% by weight of formaldehydic material (i.e. polymer plus monomer if any) and at least one mono- or polyhydric aliphatic alcohol of low dielectric constant (i.e. not greater than 33.7) as a stabilizer.  The solutions, which have a selective biological effect on cancer cells, are prepared by maintaining an aqueous solution of formaldehyde, containing methanol, ethanol or ethylene glycol, at acid pH and approximately ambient temperature for 6-10 days, then adding a further aqueous solution of polyoxymethylene to precipitate high polymeric material and to adjust the concentration of formaldehydic material to approximately 30% by weight, separating solid material from the solution and then adding at least one mono- or polyhydric aliphatic alcohol of low dielectric constant.
In an era of value-based reimbursement and high-volume surgery, the patient experience is becoming increasingly important. Despite publicized efforts to place a greater emphasis on patient-centered care, patients often report poor access to their physician, lack of effective perioperative education, and frustration as their care is commoditized.

A text-messaging (SMS) bot has the potential to help fill some of these voids. Bots are computer programs that are inherently automated to simulate human-like tasks. While a physician may wish he or she could contact each of their patients daily, it would be an impossible undertaking for most. An SMS bot could make daily contact possible by automating it, potentially improving patient education and engagement before and after surgery. Standard SMS has been previously reported to be an effective means for delivering timely information, increasing patient compliance and outcomes (medication adherence, decrease surgical infections with antiseptic showers), and reaching a socioeconomically diverse patient population. Further benefits may be seen with an SMS bot due to its automated capabilities.
The invention provides a traditional Chinese medicine composition for treating canine influenza. The traditional Chinese medicine composition is composed of the following components in parts by weight: 35-45 parts of folium eriobotryae, 5-15 parts of lily pieces, 25-35 parts of ephedra and 5-15 parts of astragalus membranaceus. The traditional Chinese medicine composition provided by the invention aims at relieving cough and reducing sputum and invigorating qi to relieve exterior syndrome, the prescription is reasonable, the preparation process is simple and the application range is wide. The traditional Chinese medicine composition provided by the invention is made from pure Chinese herbal medicine, is wide in source, low in cost, high in cure rate, free of medicine residue and free of toxic side effect, particularly, plant cell walls are broken to the maximum after superfine grinding to solve the defects of high crude fiber content and difficulty to fully dissolve effective ingredients of traditional Chinese medicine powder, and the traditional Chinese medicine composition can be more easily absorbed by dogs. The traditional Chinese medicine composition has the remarkable functions of removing dampness, stopping bleeding, tonifying the stomach and intestine and regulating body functions, the canine influenza can be effectively cured, recovery phase is shortened, and the traditional Chinese medicine composition is convenient to use. Clinical trials prove that the cure rate is higher than 90% and the traditional Chinese medicine composition has a unique curative effect.
We propose a prospective, randomized controlled study evaluating the effects of mindfulness meditation and concentration meditation on pain, fatigue, and physical functioning in patients with either multiple sclerosis MS or a generalized polyneuropathy (PN). A secondary endpoint for the MS arm will include spasticity and for the PN arm will be the physical examination findings of sensory changes and weakness. Meditation classes of 90 minutes duration will be led by a Buddhist monk with over 20 years experience in meditation. Sessions will be held once weekly over a 3-month period. There will be an initial introduction session that will last approximately 180 minutes for the adminsitration of formal instructions and a training session on how to do the meditation. Outcome assessments will be answered electronically on a secure system or in written form that will be able to be completed at home or at the site of the meditation class. The data will be directly downloaded into a queriable database. Outcome assessments will be based on the Short Form (SF)-36 health survey and Visual Analog Scale (VAS) for pain at baseline and at 3 months. Additionally, the Neuropathy Impairment Score (NIS) will be used for the PN pts. The PDDS spasticity questionnaire and the fatigue portion of the MSQLI for fatigue will be used for the MS patients. We plan to recruit adult patients with either MS or PN through the current patient population in the Mellen Center and Neuromuscular Center and flyers placed throughout the Cleveland Clinic. Patients will be excluded if they have performed meditation within the last 6 months, are cognitively impaired, or have an underlying illness that would preclude comprehension of the instructions. Other exclusion criteria include a history of symptomatic cardiopulmonary disease, uncontrolled HTN, current alcohol or drug abuse, and kidney or renal failure. Patients must be ambulatory and able to toilet themselves.
FIELD: chemical industry. SUBSTANCE: described are new compounds, namely 4-aminobenzoyl guanidines of general formula I:   wherein R 1  is A; R 2  and R 3  is each independently H, A, Ph or Het; R 2  and R 3  are together alkylene having 4 or 5 carbon atoms; Het is saturated, unsaturated or aromatic heterocycle having 1 or 2 nitrogen or sulfur atoms, bonded through N or C which is unsubstituted or mono-, di- or - trisubstituted by A, OA, NH 2 , F, Cl: Br and/or CF 3 : A is alkyl having 1-6 carbon atoms, and also physiologically acceptable salts thereof. Compounds of formula I and physiologically acceptable salts thereof have antiarrhythmic properties and act as cellular Na/H antiporter inhibitors. Also described are method of preparation thereof, pharmaceutical composition and method of inhibiting cellular Na/H antiporter. EFFECT: improved properties of the title compounds. 7 cl, 7 ex, 1 tbl
In 2009, Quill and colleagues stipulated that there are three types of sedation practices at the end of life: ordinary sedation, proportionate palliative sedation (PPS), and palliative sedation to unconsciousness (PSU). Of the three, PPS and PSU are described as "last-resort options" to relieve refractory symptoms, and PSU as the most ethically controversial type that "should be quite rare." Unfortunately, little is known about actual sedation practices at the end of life in the United States. This may be due in part to a lack of conceptual clarity about sedation in end-of-life care. We argue that, until more is known about what sedation practices occur at the end of life, and how practices can be improved by research and more specific guidelines, "palliative sedation" will remain more misunderstood and controversial than it might otherwise be. In our view, overcoming the challenges posed by sedation in end-of-life care requires: 1) greater specificity regarding clinical situations and approaches to sedation, 2) research tailored to focused clinical questions, and 3) improved training and safeguards in sedation practices. Terms like PPS and PSU are relatively simple to understand in the abstract, but their application comprises various clinical situations and approaches to sedation. An obvious barrier to empirical research on sedation practices in end-of-life care is the challenge of determining these elements, especially if not clearly communicated. Additionally, we argue that training for palliative care specialists and others should include monitoring and rescue techniques as required competencies.
Participants will receive the 10 mL epidural loading dose in 5 mL increments via the epidural catheter following catheter placement. (Current standard practice) Epidural loading dose via epidural catheter.
OBJECTIVE: Functional dyspepsia (FD), which has a complicated pathophysiologic process, is a common functional gastrointestinal disease. Gastric hypersensitivity is the key pathophysiological factor in patients with FD with chronic visceral pain. Auricular vagal nerve stimulation (AVNS) has the therapeutic effect of reducing gastric hypersensitivity by regulating the activity of the vagus nerve. However, the potential molecular mechanism is still unclear. Therefore, we investigated the effects of AVNS on the brain-gut axis through the central nerve growth factor (NGF)/ tropomyosin receptor kinase A (TrkA)/phospholipase C-gamma (PLC-γ) signaling pathway in FD model rats with gastric hypersensitivity.
MATERIALS AND METHODS: We established the FD model rats with gastric hypersensitivity by means of colon administration of trinitrobenzenesulfonic acid on ten-day-old rat pups, whereas the control rats were given normal saline. AVNS, sham AVNS, K252a (an inhibitor of TrkA, intraperitoneally), and K252a + AVNS were performed on eight-week-old model rats for five consecutive days. The therapeutic effect of AVNS on gastric hypersensitivity was determined by the measurement of abdominal withdrawal reflex response to gastric distention. NGF in gastric fundus and NGF, TrkA, PLC-γ, and transient receptor potential vanilloid 1 (TRPV1) in the nucleus tractus solitaries (NTS) were detected separately by polymerase chain reaction, Western blot, and immunofluorescence tests.
RESULTS: It was found that a high level of NGF in gastric fundus and an upregulation of the NGF/TrkA/PLC-γ signaling pathway in NTS were manifested in model rats. Meanwhile, both AVNS treatment and the administration of K252a not only decreased NGF messenger ribonucleic acid (mRNA) and protein expressions in gastric fundus but also reduced the mRNA expressions of NGF, TrkA, PLC-γ, and TRPV1 and inhibited the protein levels and hyperactive phosphorylation of TrkA/PLC-γ in NTS. In addition, the expressions of NGF and TrkA proteins in NTS were decreased significantly after the immunofluorescence assay. The K252a + AVNS treatment exerted a more sensitive effect on regulating the molecular expressions of the signal pathway than did the K252a treatment.
CONCLUSION: AVNS can regulate the brain-gut axis effectively through the central NGF/TrkA/PLC-γ signaling pathway in the NTS, which suggests a potential molecular mechanism of AVNS in ameliorating visceral hypersensitivity in FD model rats.
<P>PROBLEM TO BE SOLVED: To find a new DNA synthetase inhibitor substance and to provide its utilization method.  <P>SOLUTION: The novel DNA synthetase inhibitor substance is isolated from tobacco culture cells, then purified, and subjected to structural analysis; thus, it is made clear that the new synthetase inhibitor substance is a new dipeptide composed of homoserine and ethanolamine combined with each other by a peptide bond. The new dipeptide has an inhibition activity for selectively inhibiting a DNA synthetase ε, and its homologous compounds are also recognized as having a DNA synthetase inhibition activity. Therefore, the new dipeptide and its homologous compounds are useful as DNA synthetase inhibitors, biochemical reagents, and medicines, e.g. an anticancer agent.  <P>COPYRIGHT: (C)2005,JPO&NCIPI
PURPOSE:To provide the titled composition containing p-chlorophenoxyacetic acid as an active component, and effective to promote the blood circulation of the scalp and the function of the skin, to remove the dirt from the scalp and hair, to prevent dandruff and itchiness, and to distinctly promote the sprout and growth of the hair. CONSTITUTION:The objective composition contains p-chlorophenoxyacetic acid as an active component. The amount of the compound in the hair tonic compositioin is 0.001-5wt%, preferably 0.05-3.0wt%, and the composition may contain other components used in a conventional hair tonic composition. For example, the titled composition can be prepared by compounding 55pts.(wt.) of ethanol, 13pts. of propylene glycol, 2pts. of sodium chloride, 1.0pt. of p-chlorophenoxyacetic acid, proper amount of pigment and perfume, and >=25pts. of refined water.
Robotic donor hepatectomy is an advanced, minimally invasive surgical technique where a portion of the liver is resected from a living donor using robotic instruments. This method is known to provide enhanced precision, improved ergonomics, and superior 3D visualization.
The method for obtaining a nano-capsule structure includes at least one layer of resin deposited on a layer of substrate. The capsule nanometric in size is capable of enabling the encapsulation of a compound. The layer of resin is structured, by low voltage electron lithography, or by optical lithography or by nanoimprinting in such a way as to obtain at least one cavity in the thickness of the layer of resin. The cavity has a depth smaller than the thickness of the layer of resin. At least one layer of an encapsulating material is isotropically deposited by sputtering the material under vacuum. The cavity is sealed with a sealing material. The layer of resin is dissolved by soaking in a suitable solvent.
PCT No. PCT/SI96/00012 Sec. 371 Date Nov. 12, 1997 Sec. 102(e) Date Nov. 12, 1997 PCT Filed May 17, 1996 PCT Pub. No. WO96/36318 PCT Pub. Date Nov. 21, 1996Described is a novel three-phase pharmaceutical form with constant and controlled release of an amorphous active ingredient stabilized with polymers for a single daily peroral application, which is especially suitable for active ingredients existing in amorphous form or in one or more polymorphous forms, which exhibit poor solubility in crystal form depending on the polymorphous form, particle size and the specific surface area of the active ingredient. The active ingredient can be used in its amorphous or any polymorphous form, which in the process of the preparation of the three-phase pharmaceutical form according to the invention is converted into the amorphous form. The three-phase pharmaceutical form with constant and controlled release of an amorphous active ingredient for a single daily peroral application contains a core consisting of a first and a second phase and a coating representing the third phase. In the first phase the three-phase pharmaceutical form contains an amorphous active ingredient, the water-soluble polymer polyvinylpyrrolidone and a cellulose ether as carriers of the amorphous active ingredient and simultaneously as inhibitors of its crystallization, a surfactant that improves the solubility of the active ingredient and promotes the absorption of the amorphous active ingredient from gastrointestinal tract, in the second phase it contains a cellulose ether and a mixture of mono-, di- and triglycerides as sustained release agents and the third phase is represented by a poorly soluble or gastro-resistant film coating, which in the first few hours after the application controls the release of the active ingredient and can consist of an ester of hydroxypropylmethylcellulose with phthalic anhydride or of a copolymerizate based on methacrylic acid and ethyl acrylate. Described is also a process for the preparation of this pharmaceutical form.
PURPOSE:To provide a carrier for adsorption of an immunoactive material which does not effect agglutination reaction in lquid and has cheminal stability as well by forming said carrier of benzoguanamine particles which are fine spherical particles consisting of a cured resin or the benzoguanamine particles subjected to surface reform by silica sol. CONSTITUTION:A titled carrier consists of the benzoguanamine particles which are the condensated matter of benzoguanamine and formaldehyde, consist principally of pulverous white powdery material and has 1.41 specific gravity measured by a picnometer. Particularly the benzoguanamine particles having 1.22mum average grain size, if used, are useful as the carrier for immunological agglutination. The benzoguanamine particles coated with silica sol exhibit the smaller value than the untreated benzoguanamine particles when the contact angle is measured with the tablets formed by compression molding of both particles under the reduced pressure. Increased hydrophilicity is admitted with such particles. The improved dispersibility in an aq. medium of the benzoguanamine particles coated by the silica sol and the increased adsorptive power of protein are thus resulted.
Fruit rot is a fungal disease complex that threatens cranberry yields in North American growing operations. Management of fruit rot is especially difficult because of the diversity of the infecting fungal species, and although infections take place early in the season, the pathogens usually remain latent in the ovary until the fruit ripen. Control methods heavily rely on fungicide applications, a practice that may be limited in viability long term. Breeding for fruit rot resistance (FRR) is essential for sustainable production. It is likely that field resistance is multifaceted and involves a myriad of traits that fortify cranberry plants against the biotic and abiotic stresses contributing to fruit rot. In this study, we identified quantitative trait loci (QTL) for FRR in a segregating population. Interestingly, a QTL associated with resistance was found to overlap with one associated with fruit epicuticular wax (ECW). A single-nucleotide polymorphism genotyping assay successfully identified accessions that exhibit the desired phenotypes (i.e., less rot and more ECW), thus making it a useful tool for marker-assisted selection. Candidate genes that may contribute to FRR and ECW were also identified. This work will expedite breeding for improved cranberry fruit quality.
The invention discloses a polypeptide of fungal ubiquitin cross-linking enzyme activity, a coding sequence, a preparation method and an application thereof. The coding sequence for isolating the polypeptide is the nucleotide sequence shown in the SEQ ID NO.1 and the amino acid sequence in the SEQ ID NO.2. The preparation method comprises the steps: firstly, the total RNA of Agrocybe aegerita is extracted as a template, first-strand cDNA is obtained from RT-PCR to serve as a template, and a PCR product is obtained by PCR amplification; secondly, a PCR product and a prokaryotic expression carrier are obtained by cleavage, thus constructing a recombinant expression carrier; thirdly, the recombinant expression carrier obtained is used for transforming the host cells of Escherichia coli, thus obtaining recombinant cells for expressing an Agrocybe aegerita cross-linking enzyme; fourthly, overnight induction culture is carried out to the recombinant cells obtained, thus obtaining a saturated culture; and fifthly, the Ni<2+> affinity chromatography is utilized to purify protein and isolate and purify the polypeptide expressed by the recombinant cells. The invention discloses the application of the polypeptide in preparing the medicine for treating or preventing tumor diseases. The protein related has tumor resisting activity. The invention has very great application value in developing anti-tumor medicaments.